Sanofi SA
SNY54.660USD
-0.290-0.53%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
137.04BCap. mercado
22.64P/E TTM
Más Datos de Sanofi SA Compañía
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Información de la empresa
Código de la empresaSNY
Nombre de la empresaSanofi SA
Fecha de salida a bolsaJul 01, 2002
Fundada en1994
Director ejecutivoMr. Paul Hudson, Ph.D.
Número de empleados84587
Tipo de seguridadDepository Receipt
Fin del año fiscalJul 01
Dirección46 Avenue de la Grande Armee
CiudadPARIS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísFrance
Código postal75017
Teléfono33153774000
Sitio Webhttps://www.sanofi.com/
Código de la empresaSNY
Fecha de salida a bolsaJul 01, 2002
Fundada en1994
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
--
--
Ms. Clotilde Delbos
Ms. Clotilde Delbos
Independent Director
Independent Director
--
--
Mr. Frederic Oudea
Mr. Frederic Oudea
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Desglose de ingresos
Divisa: USDHora de actualización: dom., 6 de abr
Divisa: USDHora de actualización: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Dupixent
14.14B
31.82%
Polio / Pertrussis / Hib
2.96B
6.67%
Meningitis, Travel and endemic vaccines
1.82B
4.10%
Booster vaccines
1.42B
3.20%
Alltuviio
737.64M
1.66%
Other
23.34B
52.54%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
21.62B
48.65%
Rest of the World (Japan, South Korea, Canada, Australia, New Zealand)
13.05B
29.38%
Europe excl. France
7.80B
17.56%
France
1.96B
4.42%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Dupixent
14.14B
31.82%
Polio / Pertrussis / Hib
2.96B
6.67%
Meningitis, Travel and endemic vaccines
1.82B
4.10%
Booster vaccines
1.42B
3.20%
Alltuviio
737.64M
1.66%
Other
23.34B
52.54%
Accionista
Hora de actualización: vie., 18 de abr
Hora de actualización: vie., 18 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Dodge & Cox
2.98%
Fisher Investments
0.50%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.43%
Capital World Investors
0.32%
Other
95.32%
Estadísticas de accionistas
Accionista
Proporción
Dodge & Cox
2.98%
Fisher Investments
0.50%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.43%
Capital World Investors
0.32%
Other
95.32%
Tipo
Accionista
Proporción
Investment Advisor/Hedge Fund
5.55%
Investment Advisor
4.17%
Research Firm
0.77%
Hedge Fund
0.29%
Bank and Trust
0.07%
Pension Fund
0.02%
Family Office
0.01%
Other
89.12%
Participación institucional
Hora de actualización: dom., 19 de ene
Hora de actualización: dom., 19 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
1247
278.50M
11.02%
-14.39M
2024Q4
1263
270.44M
10.70%
-30.67M
2024Q3
1239
286.03M
11.43%
-5.72M
2024Q2
1248
275.46M
11.01%
-5.50M
2024Q1
1232
261.25M
10.33%
-7.62M
2023Q4
1213
251.25M
9.93%
-18.33M
2023Q3
1178
256.18M
10.15%
-15.97M
2023Q2
1173
257.65M
10.20%
-26.92M
2023Q1
1174
268.83M
10.66%
-6.19M
2022Q4
1167
264.16M
10.47%
-6.09M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Dodge & Cox
75.22M
2.98%
-1.08M
-1.41%
Dec 31, 2024
Fisher Investments
12.51M
0.5%
-848.08K
-6.35%
Dec 31, 2024
Invesco Advisers, Inc.
11.37M
0.45%
+303.99K
+2.75%
Dec 31, 2024
T. Rowe Price Associates, Inc.
10.84M
0.43%
+5.09M
+88.50%
Dec 31, 2024
Managed Account Advisors LLC
7.74M
0.31%
-611.48K
-7.32%
Dec 31, 2024
Barrow Hanley Global Investors
7.70M
0.3%
-140.54K
-1.79%
Dec 31, 2024
Boston Partners
5.40M
0.21%
+2.50M
+86.38%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.95M
0.2%
-3.65M
-42.49%
Dec 31, 2024
Wellington Management Company, LLP
4.48M
0.18%
-166.02K
-3.57%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
VanEck Pharmaceutical ETF
5.04%
Invesco International Dividend Achievers ETF
3.48%
Putnam Focused Large Cap Value ETF
2.86%
Pacer Global Cash Cows Dividend ETF
2.16%
Brandes US Value ETF
2.03%
Altrius Global Dividend ETF
1.99%
Pacer Trendpilot European Index ETF
1.95%
ProShares Ultra Nasdaq Biotechnology
1.59%
Invesco Nasdaq Biotechnology ETF
1.57%
Simplify Health Care ETF
1.57%
Ver más
VanEck Pharmaceutical ETF
Proporción5.04%
Invesco International Dividend Achievers ETF
Proporción3.48%
Putnam Focused Large Cap Value ETF
Proporción2.86%
Pacer Global Cash Cows Dividend ETF
Proporción2.16%
Brandes US Value ETF
Proporción2.03%
Altrius Global Dividend ETF
Proporción1.99%
Pacer Trendpilot European Index ETF
Proporción1.95%
ProShares Ultra Nasdaq Biotechnology
Proporción1.59%
Invesco Nasdaq Biotechnology ETF
Proporción1.57%
Simplify Health Care ETF
Proporción1.57%
Dividendos
Un total de
23.51B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Mar 26, 2024
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
May 10, 2024
Jun 06, 2024
May 09, 2024
Feb 15, 2023
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
May 31, 2023
Jun 23, 2023
May 30, 2023
Apr 20, 2022
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
May 05, 2022
May 31, 2022
May 04, 2022
Mar 24, 2021
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
May 04, 2021
May 26, 2021
May 03, 2021
Mar 05, 2020
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020
May 01, 2020
May 26, 2020
Apr 30, 2020
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos